# Saccharomyces cerevisiae CNCM I-3856

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/saccharomyces-cerevisiae-cncm-i-3856
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 6 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Saccharomyces cerevisiae CNCM I-3856, S. cerevisiae CNCM I-3856, CNCM I-3856, Baker's yeast strain I-3856, Probiotic yeast CNCM I-3856, S. cerevisiae strain I-3856

## Overview

Saccharomyces cerevisiae CNCM I-3856 is a [probiotic](/ingredients/condition/gut-health) yeast strain that modulates gut-brain axis signaling through tryptophan [metabolism](/ingredients/condition/weight-management) and [serotonin](/ingredients/condition/mood) regulation. This specific strain demonstrates clinically proven efficacy in reducing IBS symptoms across all subtypes, with particular benefits for abdominal pain and stool consistency.

## Health Benefits

• Reduces abdominal pain and bloating in IBS-C patients - supported by meta-analysis of 2 RCTs (n=579) showing 12.3% reduction in symptoms (PMID: 28127207)
• Improves stool consistency across IBS subtypes - RCT showed significant improvement in IBS-D (p<0.001), IBS-C, and IBS-M patients (PMID: 31807856)
• Alleviates constipation-predominant IBS symptoms - subgroup analysis of 180 IBS-C patients showed significant benefit for pain, bloating, and composite symptoms (PMID: 27403301)
• Reduces intestinal [inflammation](/ingredients/condition/inflammation) and permeability - animal studies demonstrate decreased neutrophil recruitment and enhanced barrier function (PMID: 39243351)
• May support vaginal [microbiome](/ingredients/condition/gut-health) recovery - preliminary RCT evidence suggests potential benefits (PMID: 32722250)

## Mechanism of Action

This [probiotic](/ingredients/condition/gut-health) yeast modulates the gut-brain axis by regulating tryptophan [metabolism](/ingredients/condition/weight-management) and enhancing local [serotonin production](/ingredients/condition/mood) in the intestinal mucosa. It strengthens intestinal barrier function through increased tight junction protein expression and reduces visceral hypersensitivity by modulating afferent nerve signaling. The strain also produces bioactive metabolites that influence enteric nervous system function and normalize gut motility patterns.

## Clinical Summary

A meta-analysis of 2 randomized controlled trials (n=579) demonstrated a 12.3% reduction in abdominal pain and bloating in IBS-C patients. Additional RCT evidence shows significant improvements in stool consistency across IBS-D (p<0.001), IBS-C, and IBS-M subtypes. The clinical evidence is moderate quality, with studies focusing primarily on functional gastrointestinal disorders. Most trials used dosages of 5-10 billion CFU daily for 4-8 week intervention periods.

## Nutritional Profile

Saccharomyces cerevisiae CNCM I-3856 is a [probiotic](/ingredients/condition/gut-health) yeast strain administered primarily for its bioactive and functional properties rather than macronutrient contribution. As a yeast-based organism, its nutritional composition per typical therapeutic dose (500mg or ~10 billion CFU) includes: Protein: approximately 40-50% of dry cell weight, predominantly intracellular proteins and cell wall mannoproteins (not bioavailable in intact live form); Beta-glucans: 25-35% of cell wall dry weight as (1,3)/(1,6)-beta-D-glucans, which contribute to immunomodulatory effects; Mannan-oligosaccharides (MOS): approximately 20-30% of cell wall, supporting gut microbiota modulation; B-vitamins: naturally contains thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), and folate (B9) in trace amounts per dose — insufficient to meet RDA at standard probiotic dosing; Minerals: contains intracellular selenium (as selenomethionine, strain-dependent), zinc, chromium, and iron in trace quantities; Ergosterol (provitamin D2 precursor): present in cell membrane, minimal conversion at standard dosing; Trehalose: intracellular disaccharide serving as cryoprotectant, minimal systemic contribution; Bioavailability note: As a live probiotic organism, macronutrients within intact cells are largely not bioavailable to the host; biological effects are mediated through cell wall components (beta-glucans, mannoproteins), metabolic byproducts (short-chain fatty acids, CO2), and host [immune modulation](/ingredients/condition/immune-support) rather than direct nutritional delivery. The strain is typically delivered in lyophilized capsule form at 500mg/day in clinical studies.

## Dosage & Preparation

Clinically studied doses include 1000 mg/day of whole yeast powder for 12 weeks, or 2 billion CFU twice daily (total 4 billion CFU/day) for 8 weeks. Both live and inactivated forms have been studied, with live cells showing superior effects in preclinical models. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Saccharomyces cerevisiae CNCM I-3856 is generally well-tolerated with minimal reported side effects in clinical trials. Mild gastrointestinal symptoms like initial bloating may occur during the first few days of supplementation. Immunocompromised individuals should exercise caution as fungemia risk exists, though rare with this specific strain. No significant drug interactions have been reported, but antifungal medications may reduce [probiotic](/ingredients/condition/gut-health) efficacy.

## Scientific Research

Clinical evidence includes a large RCT (n=379) showing benefits specifically in IBS-C subgroups (PMID: 27403301), and a meta-analysis of two RCTs (n=579) demonstrating 12.3% reduction in abdominal pain/discomfort (PMID: 28127207). Additional trials confirmed efficacy at 2 billion CFU twice daily for improving stool consistency across IBS subtypes (PMID: 31807856).

## Historical & Cultural Context

No traditional or historical medicinal use is documented for this specific CNCM I-3856 strain. As a proprietary modern [probiotic](/ingredients/condition/gut-health) strain developed through scientific methods, it lacks traditional medicine context.

## Synergistic Combinations

Lactobacillus acidophilus, Bifidobacterium lactis, Psyllium husk, L-glutamine, Peppermint oil

## Frequently Asked Questions

### What is the effective dosage of Saccharomyces cerevisiae CNCM I-3856 for IBS?

Clinical studies typically use 5-10 billion CFU daily for 4-8 weeks to achieve significant symptom reduction. The meta-analysis showing 12.3% improvement in IBS-C symptoms used dosages within this range consistently across trials.

### How long does it take for Saccharomyces cerevisiae CNCM I-3856 to work for IBS symptoms?

Initial improvements in stool consistency may be observed within 2-4 weeks of daily supplementation. Significant reductions in abdominal pain and bloating typically require 4-8 weeks of consistent use at therapeutic dosages.

### Can Saccharomyces cerevisiae CNCM I-3856 be taken with antibiotics?

Yes, this probiotic yeast is naturally resistant to most antibiotics unlike bacterial probiotics. It can help maintain gut microbiome balance during antibiotic treatment, though spacing doses 2-3 hours apart is recommended for optimal efficacy.

### Is Saccharomyces cerevisiae CNCM I-3856 safe for people with Crohn's disease?

While generally safe, individuals with inflammatory bowel diseases should consult healthcare providers before use. The strain may help with IBS-like symptoms in IBD patients, but specific safety data in active Crohn's disease is limited.

### Does Saccharomyces cerevisiae CNCM I-3856 survive stomach acid?

Yes, this yeast strain demonstrates excellent acid tolerance and bile resistance, allowing high survival rates through gastric transit. Studies show viable organism counts remain therapeutic after passing through the harsh stomach environment.

### What is the clinical evidence quality for Saccharomyces cerevisiae CNCM I-3856 in treating IBS symptoms?

Saccharomyces cerevisiae CNCM I-3856 is supported by a meta-analysis of 2 randomized controlled trials involving 579 patients, which demonstrated a 12.3% reduction in abdominal pain and bloating symptoms in IBS-C patients. Additional RCT evidence shows significant improvements in stool consistency across all IBS subtypes (IBS-D, IBS-C, and IBS-M), with IBS-D showing the most pronounced effect (p<0.001). This strain is one of the more rigorously studied probiotic strains for IBS-specific outcomes, though larger multi-center trials would further strengthen the evidence base.

### Who benefits most from Saccharomyces cerevisiae CNCM I-3856 supplementation?

Patients with constipation-predominant IBS (IBS-C) appear to benefit most from this strain, as clinical data specifically highlights its effectiveness in reducing abdominal pain, bloating, and improving stool consistency in this subgroup. The strain also demonstrates efficacy across other IBS subtypes including diarrhea-predominant (IBS-D) and mixed (IBS-M) presentations, though IBS-C patients show the most robust symptom relief in published analyses. Those seeking natural, non-pharmacological options for IBS symptom management are ideal candidates, particularly individuals who tolerate yeast-based probiotics well.

### How does Saccharomyces cerevisiae CNCM I-3856 compare to other common probiotic strains for IBS?

Saccharomyces cerevisiae CNCM I-3856 is uniquely a yeast-based probiotic rather than a bacterial strain, which provides a mechanistically distinct approach to gut health and may offer benefits for patients who experience side effects from bacterial probiotics. Its clinical evidence base is specifically focused on IBS symptom reduction across multiple subtypes, with documented efficacy in stool consistency improvement and abdominal symptom relief. Unlike some multi-strain formulas, this single well-characterized strain allows for clearer attribution of clinical outcomes and consistent dosing protocols in supplementation.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*